先声药业(02096.HK) 公布,旗下的抗肿瘤候选药物FGFR2b抗体偶联药物“SIM0686”,已获得中国国家药品监督管理局签发的药物临床试验批准通知书,拟开展晚期实体瘤的临床试验。
据介绍,相关药物拟开发用于治疗胃癌和肺癌等晚期恶性肿瘤。(js/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-09 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.